Filtered By:
Drug: Tamoxifen

This page shows you your search results in order of date.

Order by Relevance | Date

Total 54 results found since Jan 2013.

Fight Aging! Newsletter, January 2nd 2023
In conclusion, circulating monocytes in older adults exhibit increased expression of activation, adhesion, and migration markers, but decreased expression of co-inhibitory molecules. MERTK Inhibition Increases Bone Density via Increased Osteoblast Activity https://www.fightaging.org/archives/2022/12/mertk-inhibition-increases-bone-density-via-increased-osteoblast-activity/ Bone density results from the balance of constant activity on the part of osteoblasts and osteoclasts, the former building bone, the latter breaking it down. With advancing age, the balance of activity shifts to favor osteoclasts, prod...
Source: Fight Aging! - January 1, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

A Look Back at 2022: Progress Towards the Treatment of Aging as a Medical Condition
At the end of 2022, we can reflect on the fact that we are steadily entering a new era of medicine, one in which mechanisms of aging are targeted rather than ignored. It is a profound change, one that will change the shape of a human life and ultimately the human condition by eliminating the greatest sources of suffering and death in the world. Year after year, we see increased funding, ongoing progress towards therapies capable of slowing aging or reversing aspects of aging, and a growing taxonomy of such potential therapies and their target mechanisms. The view of aging in the medical community and public at large...
Source: Fight Aging! - December 30, 2022 Category: Research Authors: Reason Tags: Of Interest Source Type: blogs

Fight Aging! Newsletter, April 18th 2022
In conclusion, our results suggest that SAH extends lifespan by inducing MetR or mimicking its downstream effects. Since the lifespan-extending effects of SAH are conserved in yeast and nematodes, and MetR extends the lifespan of many species, exposure to SAH is expected to have multiple benefits across evolutionary boundaries. Our findings offer the enticing possibility that in humans the benefits of a MetR diet can be achieved by promoting Met reduction with SAH. The use of endogenous metabolites, such as SAH, is considered safer than drugs and other substances, suggesting that it may be one of the most feasible ways to ...
Source: Fight Aging! - April 17, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Mitochondrially Targeted Tamoxifen as a Senolytic Drug
Researchers here note that mitochondrially targeted tamoxifen, developed as a cancer therapeutic, is sufficiently senolytic to treat conditions in which senescent cells play a significant role. They have chosen to target type 2 diabetes, a case of following the money given the present epidemic of obesity. It is actually quite surprising that few of the groups developing novel senolytic drugs have set their sights on diabetes, given the solid evidence of the past few years for the pathology of both type 1 diabetes and type 2 diabetes to be mediated in large part by cellular senescence. Senescent cells play an impor...
Source: Fight Aging! - April 13, 2022 Category: Research Authors: Reason Tags: Daily News Source Type: blogs

Is it time to give up your annual mammogram?
If you dread your annual mammogram, you’re not alone. For many women, this breast cancer screening examination can be painful, stressful, and just an overall hassle. You may wonder, are you old enough to give it up? If you’re over age 75, the answer is: maybe or maybe not. The fact is, breast cancer screening isn’t right for all older adults, but there’s no expert consensus on the right age to stop. This is mostly because scientific evidence in this area is lacking, says Dr. Kathryn Rexrode, associate professor of medicine at Harvard Medical School and chief of the Division of Women’s Health at Brigham and Womenâ...
Source: Harvard Health Blog - May 1, 2020 Category: Consumer Health News Authors: Kelly Bilodeau Tags: Breast Cancer Healthy Aging Managing your health care Screening Women's Health Source Type: blogs

Medications That Can Cause Depression
There is nothing more frustrating than when the cure is part of the problem. Because depression is prevalent in patients with physical disorders like cancer, stroke, and heart disease, medications often interact with each other, complicating treatment. To appropriately manage depression, you and your physician need to evaluate all medications involved and make sure they aren’t cancelling each other out. A review in the journal Dialogues in Clinical Neuroscience a while back highlighted certain medications that can cause depression. The following are medications to watch out for. Medications to Treat Seizures and Parkinso...
Source: World of Psychology - March 31, 2019 Category: Psychiatry & Psychology Authors: Therese J. Borchard Tags: Depression Medications Drug Interactions Mood Disorder Source Type: blogs

Treatment Resistance Breast Cancer
Most breast cancers are hormone receptor positive or (ER+) and are treated with multiple therapies including chemotherapy and hormone therapies including tamoxifen and aromatase inhibitors. But the problem is then that after they metastasize,  a third of them become resistance to treatment and will cause your demise." Such endocrine therapies, including tamoxifen and aromatase inhibitor drugs, can prevent recurrence of early breast cancer, and can slow the progression of metastatic disease. However, in about one-third of patients with metastatic ER-positive breast cancer, treatment with endocrine therapies leads ...
Source: Caroline's Breast Cancer Blog - February 15, 2018 Category: Cancer & Oncology Tags: breast cancer treatment cancer research clinical trials metastatic cancer Source Type: blogs

More ' Uplifting ' News on Breast Cancer Recurrences
Sometimes I wish they would stop researching breast cancer so we stop getting such ' good ' news. New research was meant to look at whether some hormone receptor positive breast cancer patientscould stop taking tamoxifen or aromatase inhibitors such as Femara, Aromasin, or Arimidex. However they found instead that ER/PR+ breast cancers can ' smolder ' (their word, not mine) for twenty years or more, before recurring.Aromatase inhibitors and tamoxifen inhibit the production of estrogen which feeds these ER/PR+ breast cancers. The longer you are on the medication, the longer you are protected from a recurrence. However, some...
Source: Caroline's Breast Cancer Blog - February 3, 2018 Category: Cancer & Oncology Tags: breast cancer treatment cancer research frustration Source Type: blogs

New Breast Cancer Research Found A Factor that Doubles Death Risk
Isn ' t that a warm fuzzy feeling? Now I want toask my oncologist if I have this factor. But first let me see if I can explain it. This is the precis:" Researchers at Karolinska Institutet in Sweden have discovered that the risk of death from breast cancer is twice as high for patients with high heterogeneity of the estrogen receptor within the same tumour as compared to patients with low heterogeneity. The study, which is published in The Journal of the National Cancer Institute, also shows that the higher risk of death over a span of 25 years is independent of other known tumour markers and also holds true for Luminal A ...
Source: Caroline's Breast Cancer Blog - January 21, 2018 Category: Cancer & Oncology Tags: breast cancer treatment cancer research cancer risk hormone receptor status Source Type: blogs

That Lingering Risk Thingy
I can ' t say how much this just aggravates me. You get breast cancer. You get treatment and then they say we will see you once a year. You are NED (No Evidence Of Disease) for now. If you are hormone receptor positive (ER+/PR+) you get to take a little pill (tamoxifen or aromatase inhibitors) that should help you stay that way.But there is always that lingering risk of recurrence. That ' s the one thing none of us want. A newstudy which looked at data from 88 different clinical trials over more than 20 years found that the risk of recurrence lingers after the AIs are ended." Researchers from the Early Breast Cancer Triali...
Source: Caroline's Breast Cancer Blog - December 11, 2017 Category: Cancer & Oncology Tags: breast cancer treatment cancer recurrence cancer research femara Source Type: blogs

We Can Improve Care Management
As a physician and CIO, I ’m quick to spot inefficiencies in healthcare workflow. More importantly, as the care navigator for my family, I have extensive firsthand experience with patient facing processes.My wife ’s cancer treatment, my father’s end of life care, and my own recent primary hypertension diagnosis taught me how we can do better.Last week, when my wife received a rejection in coverage letter from Harvard Pilgrim/Caremark, it highlighted the imperative we have to improve care management workflow in the US.Since completing her estrogen positive, progesterone positive, HER2 negative breast cancer treat...
Source: Life as a Healthcare CIO - September 12, 2017 Category: Information Technology Source Type: blogs

Fight Aging! Newsletter, June 19th 2017
This study is the first to show that downregulation of PAPP-A expression in adult mice can significantly extend life span. Importantly, this beneficial longevity phenotype is distinct from the dwarfism of long-lived PAPP-A KO, Ames dwarf, Snell dwarf and growth hormone receptor (GHR) KO mice with germ-line mutations. Thus, downregulation of PAPP-A expression joins other treatment regimens, such as resveratrol, rapamycin and dietary restriction, which can extend life span when started in mice as adults. In a recent study, inducible knockdown of the GHR in young adult female mice increased maximal, but not median, lif...
Source: Fight Aging! - June 18, 2017 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Why Bother?
For some reason I have had a similar conversation with different women on the same topic: why take tamoxifen or aromatase inhibitors after initial breast cancer treatment. Aromatase inhibitors are Arimidex (anastrozole), Aromasin (exemestane), and Femara (letrozole)The conversations all boil down to:What if I get side effects? They have heard they are awful and could cause them some real problems. But if you don ' t even try them how will you know if you will experience the side effects?What exactly do they do? They don ' t really understand that they would reduce their recurrence risk by being on themWhy do I have to be o...
Source: Caroline's Breast Cancer Blog - March 8, 2017 Category: Cancer & Oncology Tags: doctors medications side effects Source Type: blogs

Understanding GP attitudes to cancer preventing drugs
This report aims to increase understanding of GP attitudes towards offering cancer preventing drugs and it found that nearly half of GP respondents were unaware of the potential benefits of tamoxifen, a drug that can potentially prevent breast cancer among women with a clear family history of the disease. Despite low levels of awareness, three quarters of respondents were willing to prescribe it but required greater support from specialists in secondary care.ReportSummaryPress release
Source: Health Management Specialist Library - February 13, 2017 Category: UK Health Authors: The King ' s Fund Information & Knowledge Service Tags: Quality of care and clinical outcomes Source Type: blogs

A Really Good Reason For Not Eating Tofu
I have been aided in avoiding tofu by the confusion over whether eating soy contributes to breast cancer growth. I really hate tofu. My mother fed it to us as children and I didn ' t like it then and I don ' t like it now. I might eat a little bit in my hot and sour soup but I will never order a dish which is tofu based.But now (finally) we have clarification on the soy or no soy for women with breast cancer:The issue is eating soy products seems to give women protection from breast cancer. Asian countries where soy products are eaten regularly have much lower rates of breast cancer than the US. But the estrogen-similar st...
Source: Caroline's Breast Cancer Blog - February 3, 2017 Category: Cancer & Oncology Tags: breast cancer cancer recurrence cancer risk soy tofu Source Type: blogs